Genetics

Vizgen Announces Significant Win in Ongoing Patent Litigation Against 10x Genomics and Harvard University

Retrieved on: 
Tuesday, May 7, 2024
Stem Cells, Biotechnology, Professional Services, Health, General Health, Patent Law, Health Technology, Research, Genetics, Legal, Science, Harvard University, Chromium, Harvard College, District court, Court, Defendant, Genomics, Ridesharing

Vizgen, Inc. , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University.

Key Points: 
  • Vizgen, Inc. , the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victory in its ongoing legal battle with 10x Genomics and Harvard University.
  • The U.S. District Court recently ruled in Vizgen’s favor, allowing Vizgen to expand its case based on new evidence uncovered during discovery in the litigation.
  • The Court’s ruling substantially strengthens Vizgen’s position against 10x Genomics and Harvard, who must now defend against additional allegations of antitrust violations.
  • 10x Genomics, Inc. and President and Fellows of Harvard College, Plaintiffs, v. Vizgen, Inc., Defendant.

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Retrieved on: 
Monday, May 6, 2024
Research, Genetics, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Education, FDA, CFO, Disorder, Regenerative medicine, University of California, Alexion Pharmaceuticals, PDUFA, Arena Pharmaceuticals, Danon disease, European Medicines Agency, Strategic planning, UCLA, Food, Molecule, Stanford University, Empire, BLA, Medication, Corporate communication, Definitive, Fanconi anemia, Patient, Increment, Safety, Rare disease, Regeneron Pharmaceuticals, AAV, Immunology, EMA, FA, Division, PKD, University, Marketing, MAA, Cell, Biologics license application, Pharmacology, Rare Disease Day, Disease, Mirati Therapeutics, Haematopoietic system, Gene, Society, Pyruvate kinase deficiency, Liberty Science Center, Annual general meeting, Pharmaceutical industry

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the quarter ending March 31, 2024.
  • In April, Rocket announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102 for the treatment of FA.
  • MAA acceptance was based on positive, previously disclosed data from the global RP-L102 Phase 1/2 clinical trial.
  • Mr. Ondrey was previously the CFO at Mirati Therapeutics and has held multiple senior finance leadership positions at Arena Pharmaceuticals, Alexion Pharmaceuticals, and Regeneron Pharmaceuticals.

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Retrieved on: 
Monday, May 6, 2024
Research, Genetics, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Cancer, HKEX, Therapy, Antigen, Neoplasm, Antibody, TCR, Medication, Vaccine

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.

Key Points: 
  • Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland.
  • The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice.
  • BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.
  • “We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen.

Seek Labs Announces Successful Completion of African Swine Fever Virus In Vivo Trial Utilizing CRISPR-based Treatments

Retrieved on: 
Monday, May 6, 2024
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Health, Agriculture, Natural Resources, Science, Other Science, Mortality, African swine fever virus, Viral disease, CRISPR, Gene targeting, Hope, White, Chicken, Synthetic control method, Blood, ASF, Classical swine fever, Cas, ELISA, Animal, Survival, Litopenaeus, Infection, Doctor of Philosophy, Disease, ASFV, Real-time, Food security, Viral load, Food, Seek, H5N1, Genome, Candidate, Viral, Pharmacy, Injection, WSSV, Medication, Vaccine

Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs.

Key Points: 
  • Seek Labs, a healthcare innovations company developing next-generation point-of-care molecular diagnostic systems and novel CRISPR-based gene therapies, announced today the successful completion of a therapeutic trial using innovative CRISPR-based technologies to target the African Swine Fever Virus (ASFV) in pigs.
  • The trial, which aimed to replicate and expand an earlier trial, demonstrated pigs infected with ASFV and treated with Seek Labs’ CRISPR-based systems survived longer than untreated infected pigs.
  • With no available treatments for African Swine Fever, this is a breakthrough discovery.
  • Seek Labs’ work represents a beacon of hope for the swine industry and underscores the transformative potential of CRISPR-based technology in global healthcare.

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
Monday, May 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Retrieved on: 
Monday, May 6, 2024
Health, Genetics, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, The Association, License, ADOA, Dravet syndrome, Cognition, MECP2, SYNGAP1, RNA, Rett syndrome, Acadia Pharmaceuticals, Cell, Conference, Seizure, CNS, Therapy, OLE, Patient, Gene, Society, Medicine, Collaboration, Central nervous system, Behavior, ARVO, Pharmaceutical industry

“In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.

Key Points: 
  • “In the first quarter of 2024, Stoke took a major step forward in our effort to advance the first potential disease-modifying medicine for patients with Dravet syndrome,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics.
  • These data showed substantial and durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior that support the potential for disease modification.
  • The Company expanded and strengthened its management team with the appointments of Jason Hoitt as Chief Commercial Officer and Thomas (Tommy) Leggett as Chief Financial Officer.
  • General and administrative expenses for the three months ended March 31, 2024 were $10.2 million, compared to $10.2 million for the same period in 2023.

ArsenalBio Announces Presentation of Four Abstracts at ASGCT Annual Meeting Highlighting New Mechanisms for Leveraging CAR T Cells to Address Solid Tumor Cancers

Retrieved on: 
Monday, May 6, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, ISH, PSMA, CD3, CA9, Payload, CRISPR, SPA, Risk, Tissue, ICT, Abstract, Immunosuppression, Cytokine, Tumor microenvironment, Cell, Research, Primer, Downregulation and upregulation, Engineering, DNA, Science, Gene, Society, Neoplasm, Antigen, Messenger, Information and communications technology, Immune system, Kidney cancer, In situ hybridization, Ovarian cancer, Vaccine

These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).

Key Points: 
  • These data highlight the portfolio of solutions ArsenalBio is developing to address unmet need in solid tumor cancers, including those currently being studied as potential treatments for ovarian cancer ( NCT05617755 ) and kidney cancer ( NCT06245915 ).
  • It integrates an “AND” logic gate designed to limit off-tumor toxicity through a requirement for dual tumor antigen recognition.
  • T cell exhaustion from chronic antigen stimulation and an immunosuppressive tumor microenvironment limits the efficacy of T cell therapies used to treat solid tumors.
  • This research used CRISPR/Cas9-based screening, paired with deep sequencing, to identify intrinsic genetic perturbations that can prevent T cell exhaustion.

Promega Kit Enables European Forensic Labs to Solve Challenging Cold Cases

Retrieved on: 
Tuesday, May 7, 2024
Health, Biometrics, Health Technology, Genetics, Other Science, Science, Biotechnology, Multimedia, Spectrum, STR, DNA, Promega

Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples.

Key Points: 
  • Forensic laboratories in Europe now have a new DNA analysis kit to efficiently process challenging casework samples.
  • The PowerPlex® 18E System, launched by Promega Corporation, uses eight-color short tandem repeat (STR) analysis chemistry to extract more usable information from challenging samples.
  • The kit includes all DNA markers recommended by the European Network of Forensic Science Institutes (ENFSI).
  • “This kit meets European forensic laboratories’ unique needs while also giving them more information from challenging DNA samples compared to earlier chemistries.”
    STR analysis is the most widely used tool in human identification efforts.

Inocras Hong Kong Limited, in Collaboration with Cancerinformation.com.hk Charity Foundation and Sponsored by AstraZeneca Hong Kong, Offers Free BRCA or HRD Genetic Testing for Eligible Cancer Patients in Hong Kong and Macau

Retrieved on: 
Tuesday, May 7, 2024
Oncology, Health, Genetics, Health Technology, Research, Science, Breast cancer, HRD, Cancer, Pancreatic cancer, Partnership, Genetic testing, Prostate cancer, BRCA, CICF, Patient, Physician, Medicine, Ovarian cancer, AstraZeneca, Tutoring

Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.

Key Points: 
  • Inocras Hong Kong, in partnership with Cancerinformation.com.hk Charity Foundation (CICF) and generously sponsored by AstraZeneca Hong Kong, is pleased to announce the launch of 'HRDetect' Program offering free BRCA or HRD genetic testing for eligible cancer patients in Hong Kong and Macau.
  • Eligible patients in both the private and public sectors can apply for the free genetic tests through their physicians.
  • The program will offer BRCA or HRD testing to eligible patients diagnosed with breast cancer and ovarian cancer, prostate cancer and pancreatic cancer.
  • "We are proud to leverage our cutting-edge technology and expertise to offer free genetic testing services to eligible cancer patients in Hong Kong and Macau," said Stephanie Sunkyung Yang, CEO of Inocras Hong Kong Limited.